As of October 1, 2015, ICD-10-CM diagnosis codes replaced the previous ICD-9-CM diagnosis codes in all health care settings for diagnosis reporting. ICD-9 codes are no longer accepted or provided evidence of medical necessity for ordered laboratory services.
Please see our summary of changes that specifically pertain to the diagnosis codes that may indicate PancraGen™.
PancraGen, powered by PathfinderTG, is covered under local Medicare policy L34864 – Loss of Heterozygosity Based Topographic Genotyping with PathfinderTG. You can reference this policy on the CMS website at: http://go.cms.gov/1iePqm5. Also available on the CMS website is additional information for providers regarding ICD-10: www.cms.hhs.gov/icd10. Diagnosis codes submitted with test orders should always be based upon what can be supported within the patient’s medical record.
At Interpace Diagnostics, we are committed to providing patients with access to personalized medicine, regardless of their personal financial situation.
Since coverage differs by insurance plan, Interpace Diagnostics has implemented the COMPASS* Program, which offers needs-based financial assistance and payment plans. All tests provided by Interpace Diagnostics are covered in the COMPASS Program.
Interpace Diagnostics tailors financial assistance solutions for patients, accounting for factors such as income and family unit size. Tiered discounts are based on guidelines provided by the US Department of Health and Human Services and can be as much as 100% of your amount due. All patients are encouraged to apply.
Interest free payment plans are available to all patients unable to pay their full balance by the due date.
*COMPASS is not available to patients covered by Medicare, Medicaid, or any other government program, or where the program is restricted or prohibited by contractual obligation, or federal or state law.